« Return to News | Study Conduct

Schulman Associates IRB Expands into Canada

Tuesday, November 3, 2009 08:31 AM

Cincinnati-based Schulman Associates IRB has expanded its institutional review board (IRB) services into Canada. For North American studies, which are conducted in both the U.S. and Canada, Canadian and U.S. board members will review the research together to maintain consistency.

“Our clients have asked us to provide review services in Canada.  Now that our Canadian IRB is operational, Schulman can provide the same high quality review for Canadian research as it has provided in the U.S. for the past 26 years,” said John Isidor, Schulman’s CEO.

Schulman provides clients conducting Canadian studies with access to its WebPortal 2.0 service.  WebPortal 2.0 interfaces directly with Schulman’s internal system to provide sponsors and CROs with real-time updates on review status and timelines.

Schulman’s Canadian office is located in Toronto.  French-speaking support is available for Canadian studies. Schulman’s U.S. IRB is fully accredited by the Association for Accreditation of Human Research Protection Programs (AAHRPP).  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.